These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

672 related items for PubMed ID: 31712073

  • 21. Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients.
    Berhane S, Toyoda H, Tada T, Kumada T, Kagebayashi C, Satomura S, Schweitzer N, Vogel A, Manns MP, Benckert J, Berg T, Ebker M, Best J, Dechêne A, Gerken G, Schlaak JF, Weinmann A, Wörns MA, Galle P, Yeo W, Mo F, Chan SL, Reeves H, Cox T, Johnson P.
    Clin Gastroenterol Hepatol; 2016 Jun; 14(6):875-886.e6. PubMed ID: 26775025
    [Abstract] [Full Text] [Related]

  • 22. The GALAD score and the BALAD-2 score correlate with transarterial and systemic treatment response and survival in patients with hepatocellular carcinoma.
    Olbrich A, Niemeyer J, Seiffert H, Ebel S, Gros O, Lordick F, Forstmeyer D, Seehofer D, Rademacher S, Denecke T, Matz-Soja M, Berg T, van Bömmel F.
    J Cancer Res Clin Oncol; 2024 Feb 06; 150(2):81. PubMed ID: 38319485
    [Abstract] [Full Text] [Related]

  • 23. A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma.
    Ertle JM, Heider D, Wichert M, Keller B, Kueper R, Hilgard P, Gerken G, Schlaak JF.
    Digestion; 2013 Feb 06; 87(2):121-31. PubMed ID: 23406785
    [Abstract] [Full Text] [Related]

  • 24. Refinement and validation of a comprehensive clinical diagnostic model (GAMAD) based on gender, age, multitarget circulating tumour DNA methylation signature and commonly used serological biomarkers for early detection of hepatocellular carcinoma: a multicentre, prospective observational study protocol.
    Yang T, Wang N, Wang F, Liu H, Shen F, Lv G.
    BMJ Open; 2023 Sep 18; 13(9):e076467. PubMed ID: 37723113
    [Abstract] [Full Text] [Related]

  • 25. GALAD outperforms aMAP and ALBI for predicting HCC in patients with compensated advanced chronic liver disease: A 12-year prospective study.
    Villa E, Donghia R, Baldaccini V, Tedesco CC, Shahini E, Cozzolongo R, Ascari S, Pesole PL, Coletta S, Critelli RM, Lasagni S, Schepis F, Semellini F, Giannelli G.
    Hepatol Commun; 2023 Oct 01; 7(10):. PubMed ID: 37708455
    [Abstract] [Full Text] [Related]

  • 26. GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score.
    Yang JD, Addissie BD, Mara KC, Harmsen WS, Dai J, Zhang N, Wongjarupong N, Ali HM, Ali HA, Hassan FA, Lavu S, Cvinar JL, Giama NH, Moser CD, Miyabe K, Allotey LK, Algeciras-Schimnich A, Theobald JP, Ward MM, Nguyen MH, Befeler AS, Reddy KR, Schwartz M, Harnois DM, Yamada H, Srivastava S, Rinaudo JA, Gores GJ, Feng Z, Marrero JA, Roberts LR.
    Cancer Epidemiol Biomarkers Prev; 2019 Mar 01; 28(3):531-538. PubMed ID: 30464023
    [Abstract] [Full Text] [Related]

  • 27. Validation of the GALAD model for early diagnosis and monitoring of hepatocellular carcinoma in Chinese multicenter study.
    Huang C, Fang M, Xiao X, Wang H, Gao Z, Ji J, Liu L, Gu E, Li Y, Wang M, Gao C.
    Liver Int; 2022 Jan 01; 42(1):210-223. PubMed ID: 34679250
    [Abstract] [Full Text] [Related]

  • 28. Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case-Control Study.
    Piratvisuth T, Tanwandee T, Thongsawat S, Sukeepaisarnjaroen W, Esteban JI, Bes M, Köhler B, He Y, Swiatek-de Lange M, Morgenstern D, Chan HL.
    Hepatol Commun; 2022 Apr 01; 6(4):679-691. PubMed ID: 34796691
    [Abstract] [Full Text] [Related]

  • 29. Diagnostic Role of Blood Tumor Markers in Predicting Hepatocellular Carcinoma in Liver Cirrhosis Patients Undergoing Liver Transplantation.
    Kim Y, Park YH, Hwang S, Kim KH, Ahn CS, Moon DB, Ha TY, Song GW, Jung DH, Park GC, Lee SG.
    Ann Transplant; 2016 Oct 25; 21():660-667. PubMed ID: 27777395
    [Abstract] [Full Text] [Related]

  • 30. Diagnostic Value of Serum Biomarkers for Patients Undergoing Curative Resection with Non-B, Non-C Hepatocellular Carcinoma.
    Li Y, Chen Y, Chen J.
    J Coll Physicians Surg Pak; 2020 Feb 25; 30(2):134-138. PubMed ID: 32036818
    [Abstract] [Full Text] [Related]

  • 31. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease.
    Beale G, Chattopadhyay D, Gray J, Stewart S, Hudson M, Day C, Trerotoli P, Giannelli G, Manas D, Reeves H.
    BMC Cancer; 2008 Jul 18; 8():200. PubMed ID: 18638391
    [Abstract] [Full Text] [Related]

  • 32. Des-γ carboxyprothrombin may not be a good biomarker for hepatocellular carcinoma in those chronically infected with hepatitis B virus with basal core promoter double mutations (T^{1762}, A^{1764}), a prospective study.
    Li GJ, Chen QY, Harrison TJ, Wang XY, Hu LP, Yang QL, Li KW, Fang ZL.
    Cancer Biomark; 2017 Jul 18; 18(3):241-248. PubMed ID: 28085009
    [Abstract] [Full Text] [Related]

  • 33. Diagnostic accuracy of des-gamma-carboxy prothrombin for hepatocellular carcinoma in a French cohort using the Lumipulse® G600 analyzer.
    Sultanik P, Ginguay A, Vandame J, Popovici T, Meritet JF, Cynober L, Pol S, Bories PN.
    J Viral Hepat; 2017 Jan 18; 24(1):80-85. PubMed ID: 27699936
    [Abstract] [Full Text] [Related]

  • 34. Glycopeptide Biomarkers in Serum Haptoglobin for Hepatocellular Carcinoma Detection in Patients with Nonalcoholic Steatohepatitis.
    Zhu J, Huang J, Zhang J, Chen Z, Lin Y, Grigorean G, Li L, Liu S, Singal AG, Parikh ND, Lubman DM.
    J Proteome Res; 2020 Aug 07; 19(8):3452-3466. PubMed ID: 32412768
    [Abstract] [Full Text] [Related]

  • 35. Highly sensitive alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection.
    Caviglia GP, Abate ML, Petrini E, Gaia S, Rizzetto M, Smedile A.
    Hepatol Res; 2016 Mar 07; 46(3):E130-5. PubMed ID: 26082262
    [Abstract] [Full Text] [Related]

  • 36. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma.
    Sterling RK, Jeffers L, Gordon F, Venook AP, Reddy KR, Satomura S, Kanke F, Schwartz ME, Sherman M.
    Clin Gastroenterol Hepatol; 2009 Jan 07; 7(1):104-13. PubMed ID: 18849011
    [Abstract] [Full Text] [Related]

  • 37. A Novel Blood-Based Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma.
    Chalasani NP, Ramasubramanian TS, Bhattacharya A, Olson MC, Edwards V DK, Roberts LR, Kisiel JB, Reddy KR, Lidgard GP, Johnson SC, Bruinsma JJ.
    Clin Gastroenterol Hepatol; 2021 Dec 07; 19(12):2597-2605.e4. PubMed ID: 32889146
    [Abstract] [Full Text] [Related]

  • 38. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma.
    Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, Morgan TR, Kim HY, Lee WM, Bonkovsky HL, Dienstag JL, HALT-C Trial Group.
    Gastroenterology; 2010 Feb 07; 138(2):493-502. PubMed ID: 19852963
    [Abstract] [Full Text] [Related]

  • 39. Diagnostic value of alpha-fetoprotein, Lens culinaris agglutinin-reactive alpha-fetoprotein, and des-gamma-carboxyprothrombin in hepatitis B virus-related hepatocellular carcinoma.
    Song T, Wang L, Su B, Zeng W, Jiang T, Zhang T, Sun G, Wu H.
    J Int Med Res; 2020 Mar 07; 48(3):300060519889270. PubMed ID: 31852373
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.